Whats new

Whats new.

Maxim - Positive Response Data for Efti + Keytruda in 1L H&N Cancer, Cohort B; Reiterate Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

July 12th 2024

For a copy of this analyst report please contact your Maxim advisor

Go back